Copyright © 2002 by the European Society of Cardiology.
Impact of heart failure and left ventricular systolic dysfunction on quality of life. A cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population
a Department of Primary Care and General Practice, Primary Care Clinical Sciences Building, University of Birmingham, Birmingham, U.K.
b Department of Cardiology, Selly Oak Hospital, Birmingham, U.K.
revised March 25, 2002; accepted March 27, 2002
Abstract
Background Heart failure and left ventricular systolic dysfunction (LVSD) are increasingly common disorders, with outcomes worse than many cancers. Evidence-based therapies, such as ACE inhibitors and beta-blockers, improve prognosis and symptoms, and reduce healthcare expenditure. However, despite the high prevalence and malignant prognosis, few studies have reported the impact of heart failure and LVSD on overall quality of life and, more crucially, have not researched the elderly or those in the community.
Methods All patients attending the Echocardiographic Heart of England Screening (ECHOES) study of the prevalence of heart failure and LVSD in the community were assessed by clinical history and examination, electrocardiogram and echocardiography, and also completed the SF36 health status questionnaire. Quality of life in patients found to have heart failure, LVSD, and other cardiac and medical conditions are compared with the randomly selected general population sample. Data are generalisable to the UK.
Results 6162 people in the community were screened in the ECHOES study, of whom 5961 (97%) completed the SF36. The health perceptions of 3850 people aged 45 years or older selected randomly from the population were compared with those of 426 patients diagnosed as having definite heart failure. Those with heart failure had significant impairment of all the measured aspects of physical and mental health, in addition to declines in physical functioning. Significantly worse impairment was found in those with more severe heart failure by NYHA class: indeed, NYHA functional class was closely correlated to SF36 score. Patients with asymptomatic left ventricular dysfunction and patients rendered asymptomatic by treatment had similar scores to the random population sample. Those with heart failure reported more severe physical impairment of quality of life than people giving a history of chronic lung disease or arthritis, with less impact on mental health than patients reporting depression.
Conclusions Patients with heart failure have statistically significant impairment of all aspects of quality of life, not simply physical functioning. The physical (role and functioning) health burden was significantly greater than that suffered in other serious common chronic disorders, whether cardiac or other systems. Optimising treatment to improve NYHA class appears to improve perceptions of quality of life for patients with heart failure. Given the dramatic decline in quality of life with heart failure, this end-point should be a much more important target for healthcare interventions, especially treatments such as ACE inhibitors and beta-blockers that are shown to improve quality of life. Copyright 2002 The European Society of Cardiology. Published by Elsevier Science Ltd. All rights reserved
Key Words: Heart failure, LVSD, quality of life.
f1 Correspondence: F. D. R. Hobbs, Department of Primary Care and General Practice, Primary Care Clinical Sciences Building, University of Birmingham, Birmingham B15 2TT, U.K.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. J. Barrett-Lee, J. M. Dixon, C. Farrell, A. Jones, R. Leonard, N. Murray, C. Palmieri, C. J. Plummer, A. Stanley, and M. W. Verrill Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk Ann. Onc., May 1, 2009; 20(5): 816 - 827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Jaarsma, J. M. Beattie, M. Ryder, F. H. Rutten, T. McDonagh, P. Mohacsi, S. A. Murray, T. Grodzicki, I. Bergh, M. Metra, et al. Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology Eur J Heart Fail, May 1, 2009; 11(5): 433 - 443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J Calvert, A. Shankar, R. J McManus, R. Ryan, and N. Freemantle Evaluation of the management of heart failure in primary care Fam. Pract., April 1, 2009; 26(2): 145 - 153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. McMurray, M. Petrie, K. Swedberg, M. Komajda, S. Anker, and R. Gardner CHAPTER 23 Heart Failure ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Johansen, S. S. Pedersen, H. Spindler, K. Andersen, J. C. Nielsen, and P. T. Mortensen Symptomatic heart failure is the most important clinical correlate of impaired quality of life, anxiety, and depression in implantable cardioverter-defibrillator patients: a single-centre, cross-sectional study in 610 patients Europace, May 1, 2008; 10(5): 545 - 551. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Thomas, D. W. Chapa, E. Friedmann, C. Durden, A. Ross, M. C. Y. Lee, and H.-J. Lee Depression in Patients With Heart Failure: Prevalence, Pathophysiological Mechanisms, and Treatment Crit. Care Nurse, April 1, 2008; 28(2): 40 - 55. [Full Text] [PDF]
|
|
|
|
|
|
A. Bayes-Genis, R. Vazquez, T. Puig, C. Fernandez-Palomeque, J. Fabregat, A. Bardaji, D. Pascual-Figal, J. Ordonez-Llanos, M. Valdes, A. Gabarrus, et al. Left atrial enlargement and NT-proBNP as predictors of sudden cardiac death in patients with heart failure Eur J Heart Fail, August 1, 2007; 9(8): 802 - 807. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J Johnson Management of end stage cardiac failure Postgrad. Med. J., June 1, 2007; 83(980): 395 - 401. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F.D. R. Hobbs, A. K. Roalfe, R. C. Davis, M. K. Davies, R. Hare, and and the Midlands Research Practices Consortium (Mi Prognosis of all-cause heart failure and borderline left ventricular systolic dysfunction: 5 year mortality follow-up of the Echocardiographic Heart of England Screening Study (ECHOES) Eur. Heart J., May 1, 2007; 28(9): 1128 - 1134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. V. Mikkelsen, J. E. Moller, P. Bie, H. Ryde, L. Videbaek, and T. Haghfelt Tei index and neurohormonal activation in patients with incident heart failure: Serial changes and prognostic value Eur J Heart Fail, October 1, 2006; 8(6): 599 - 608. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Schlosshan, D. Barker, C. Pepper, G. Williams, C. Morley, and L.-B. Tan CRT improves the exercise capacity and functional reserve of the failing heart through enhancing the cardiac flow- and pressure-generating capacity Eur J Heart Fail, August 1, 2006; 8(5): 515 - 521. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J.V. McMurray, F. L. Andersson, S. Stewart, K. Svensson, A. C. Solal, R. Dietz, J. Vanhaecke, D. J. van Veldhuisen, J. Ostergren, C. B. Granger, et al. Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur. Heart J., June 1, 2006; 27(12): 1447 - 1458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Marty, M. Espie, A. Llombart, A. Monnier, B. L. Rapoport, V. Stahalova, and On behalf of the Dexrazoxane Study Group Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane(R)) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy Ann. Onc., April 1, 2006; 17(4): 614 - 622. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gott, S. Barnes, C. Parker, S. Payne, D. Seamark, S. Gariballa, and N. Small Predictors of the quality of life of older people with heart failure recruited from primary care Age Ageing, March 1, 2006; 35(2): 172 - 177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. J. Remme, J. J.V. McMurray, B. Rauch, F. Zannad, K. Keukelaar, A. Cohen-Solal, J. Lopez-Sendon, F.D. R. Hobbs, D. E. Grobbee, A. Boccanelli, et al. Public awareness of heart failure in Europe: first results from SHAPE Eur. Heart J., November 2, 2005; 26(22): 2413 - 2421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.D. R. Hobbs, J. Korewicki, J. G.F. Cleland, J. Eastaugh, N. Freemantle, and on behalf of the IMPROVEMENT Investigators The diagnosis of heart failure in European primary care: The IMPROVEMENT Programme survey of perception and practice Eur J Heart Fail, August 1, 2005; 7(5): 768 - 779. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Razvi, L. E Ingoe, C. V McMillan, and J. U Weaver Health status in patients with sub-clinical hypothyroidism Eur. J. Endocrinol., May 1, 2005; 152(5): 713 - 717. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Calvert, N. Freemantle, and J. G.F. Cleland The impact of chronic heart failure on health-related quality of life data acquired in the baseline phase of the CARE-HF study Eur J Heart Fail, March 2, 2005; 7(2): 243 - 251. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Incalzi, A. Corsonello, C. Pedone, F. Corica, P. Carbonin, R. Bernabei, and on Behalf of the GIFA Investigators Construct Validity of Activities of Daily Living Scale: A Clue To Distinguish the Disabling Effects of COPD and Congestive Heart Failure Chest, March 1, 2005; 127(3): 830 - 838. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Sosin, G. S. Bhatia, R. C. Davis, and G. Y.H. Lip Heart failure--the importance of ethnicity Eur J Heart Fail, December 1, 2004; 6(7): 831 - 843. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. O'Connor and K. E. Joynt Depression: are we ignoring an important comorbidity in heart failure? J. Am. Coll. Cardiol., May 5, 2004; 43(9): 1550 - 1552. [Full Text] [PDF]
|
|
|
|
|
|
A. Bayes-Genis, M. Santalo-Bel, E. Zapico-Muniz, L. Lopez, C. Cotes, J. Bellido, R. Leta, P. Casan, and J. Ordonez-Llanos N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction Eur J Heart Fail, March 15, 2004; 6(3): 301 - 308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. E. Hagens, A. V. Ranchor, E. Van Sonderen, H. A. Bosker, O. Kamp, J. G. P. Tijssen, J. H. Kingma, H. J. G. M. Crijns, I. C. Van Gelder, and the RACE Study Group Effect of rate or rhythm control on quality of life in persistent atrial fibrillation: Results from the Rate Control Versus Electrical Cardioversion (RACE) study J. Am. Coll. Cardiol., January 21, 2004; 43(2): 241 - 247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Muller, G. Gamba, F. Jaquet, and B. Hess Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV--efficacy and quality of life Eur J Heart Fail, December 1, 2003; 5(6): 793 - 801. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A B Rao and D Gray Breathlessness in hospitalised adult patients Postgrad. Med. J., December 1, 2003; 79(938): 681 - 685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Thulasimani and M Ramaswamy Suggestions to improve the quality of life in heart failure Eur. Heart J., September 2, 2003; 24(18): 1700 - 1700. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Murray-Thomas and M. R Cowie Epidemiology and clinical aspects of congestive heart failure Journal of Renin-Angiotensin-Aldosterone System, September 1, 2003; 4(3): 131 - 136. [Abstract] [PDF]
|
|
|
|
|
|
R. Archana and D. Gray The quality of life in chronic disease--heart failure is as bad as it gets Eur. Heart J., December 1, 2002; 23(23): 1806 - 1808. [Full Text] [PDF]
|
|